https://www.businesswire.com/news/home/20191023005068/en/ > CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 23, 2019-- > Elicio Therapeutics, a next generation immuno-oncology company, announced today that Christopher Haqq M.D., Ph.D. has joined Elicio as Executive Vice President, Head of Research and Development, and Chief Medical Officer.